SCHEMBL291507

SCHEMBL291507

[CH](c1ccccc1)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
CA1 P00915 2/20 0.48
MGLL Q99685 2/20 0.48
TP53 P04637 1/20 0.48
TAAR1 Q96RJ0 2/20 0.46
MAPK1 P28482 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MMP3 P08254 1/20 0.46
BCL2L1 Q07817 1/20 0.46
HDAC2 Q92769 2/20 0.43
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
MAOB P27338 2/20 0.41
TSHR P16473 1/20 0.41
CYP2A6 P11509 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2839493 0.97 ALDH1A1 (0.56) ALDH1A1CA1MGLLTP53TAAR1
SCHEMBL2357484 0.87 ALDH1A1 (0.50) ALDH1A1CA1MAPK1CYP1A2HDAC2
SCHEMBL9140874 0.85 CYP1A2 (0.71) ALDH1A1CA1MGLLTP53CYP1A2
SCHEMBL1302 0.84 ALDH1A1 (0.53) ALDH1A1CA1MAPK1CYP1A2HDAC2
SCHEMBL4004894 0.82 CA1 (0.60) ALDH1A1CA1MGLLTP53HDAC2
SCHEMBL11548251 0.82 CA1 (0.60) ALDH1A1CA1MGLLTP53HDAC2
SCHEMBL11548255 0.82 CA1 (0.60) ALDH1A1CA1MGLLTP53HDAC2
SCHEMBL4004892 0.82 CA1 (0.60) ALDH1A1CA1MGLLTP53HDAC2
SCHEMBL28995582 0.81 ALDH1A1 (0.50) ALDH1A1CA1MAPK1CYP1A2HDAC2
SCHEMBL22711559 0.81 ALDH1A1 (0.50) ALDH1A1CA1MAPK1CYP1A2HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2727915-B1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof CONCERT PHARMACEUTICALS INC (US) 2016-04-13 EP claimed
EP-2727915-A1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof Concert Pharmaceuticals Inc. (US) 2014-05-07 EP claimed
US-20020045574-A1 Glycopeptide antibacterial compounds and methods of using same PRINCETON UNIVERSITY 2002-04-18 US claimed
WO-2001081373-A2 GLYCOPEPTIDE ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME MERCK & CO., INC. (US) 2001-11-01 WO claimed
CN-114736219-B Antitumor compounds 法马马有限公司 2024-06-07 CN disclosed
CN-114751920-B Antitumor compounds 法马马有限公司 2024-06-07 CN disclosed
CN-118139851-A Antitumor compounds 法马马有限公司 2024-06-04 CN disclosed
US-11999757-B2 Synthesis of boronate ester derivatives and uses thereof MELINTA SUBSIDIARY CORP. (US) 2024-06-04 US disclosed
US-20240166666-A1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2024-05-23 US disclosed
CN-117986153-A Ionizable cationic lipid compound, and preparation method and application thereof 晟迪生物医药(苏州)有限公司 2024-05-07 CN disclosed
US-20240131180-A1 DRUG ANTIBODY CONJUGATES PHARMA MAR, S.A. (ES) 2024-04-25 US disclosed
EP-4356736-A2 SYNTHESIS OF BORONATE SALTS Melinta Therapeutics, Inc. (US) 2024-04-24 EP disclosed
US-20090186938-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2009-07-23 US disclosed
WO-2009080761-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2009-07-02 WO disclosed
WO-2009080769-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2009-07-02 WO disclosed
WO-2009077401-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2009-06-25 WO disclosed
US-20090143432-A1 Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof CONCERT PHARMACEUTICALS, INC. (US) 2009-06-04 US disclosed
EP-2032551-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2009-03-11 EP disclosed
WO-2007144423-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS PHARMA MAR, S.A. (ES) 2007-12-21 WO disclosed
US-5508273-A ARALKYLPHOSPHONATES FOR OSTEOPOROSIS ORTHO PHARMACEUTICAL CORPORATION (US) 1996-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240131180-A1 DRUG ANTIBODY CONJUGATES STT3B, STT3A, TTL ALDH1A1 785/4885CA1 2782/4885MGLL 2396/4885
US-11999757-B2 Synthesis of boronate ester derivatives and uses thereof ADH5, ADH1A, ADH7 ALDH1A1 69/4885CA1 1463/4885MGLL 498/4885
US-20090143432-A1 Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof COMT, DRD2, DRD3 ALDH1A1 478/4885CA1 2781/4885MGLL 4345/4885
US-20240166666-A1 ANTITUMORAL COMPOUNDS TP53, TOP1, MCL1 ALDH1A1 144/4885CA1 567/4885MGLL 2818/4885
US-20090186938-A1 ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS RPLP1, PKD1, KRAS ALDH1A1 1692/4885CA1 299/4885MGLL 4358/4885
US-20020045574-A1 Glycopeptide antibacterial compounds and methods of using same FUT6, DAO, B3GAT3 ALDH1A1 4402/4885CA1 3758/4885MGLL 2285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.